Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies to sponsor CHEST 2026 CyPath Lung presentation on October 21

Neutral Impact 2 of 5 other Written later

bioAffinity Technologies said it will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the use of its CyPath Lung test in lung cancer risk assessment and pulmonary nodule management. The filing includes no financial results, guidance, or financing terms, so the announcement is an event update rather than a change in the company's financial position.

Key points

  • Presentation is scheduled for October 21, 2026, from 12:30 to 1:15 p.m. MST in Learning Theater 4 at the Phoenix Convention Center, Phoenix, Arizona.
  • Chief Medical Officer Gordon H. Downie, MD, PhD, is listed as the presenter.
  • The presentation will discuss preliminary research on a new asthma and COPD test, which the filing describes as investigational and not available for clinical use.
  • The company's Medical and Scientific Advisory Board will also meet in conjunction with CHEST 2026.

The filing

CompanybioAffinity Technologies, Inc. (BIAF)
Form8-K, current report
Filed with the SECOct 15, 2026, 9:30 AM ET
Accession number0001493152-26-047168

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.